Kathy Katella

Akiko Iwasaki is a professor of immunobiology at Yale School of Medicine and an investigator of the Howard Hughes Medical Institute. Her research focuses on understanding COVID-19 to aid in prevention and treatment of the disease. She has been extensively quoted by newspapers and reporters due to her expertise in the field, and has gained a large following on Twitter for her research updates. Iwasaki's work around COVID-19 has raised her media profile considerably. She is a key figure in scientific research related to SARS-CoV-2, contributing to a growing body of knowledge about how autoimmunity plays a role in severe COVID-19 illness. She has published almost two dozen papers addressing various COVID-19 related questions, ranging from new mouse models to help researchers replicate and study the virus, to the use of a saliva test for diagnosis and determining who will develop complications from the disease.

Biography:  https://www.yalemedicine.org/news/covid-19-research-patient-care

32%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a poor reputation for journalistic standards and is not considered a reliable news source.

Bias

10%

Examples:

  • Akiko Iwasaki's primary mission is to contribute to a greater understanding of SARS-CoV-2 to aid in prevention and treatment of the disease.
  • Iwasaki believes that public education is a key ingredient for slowing the spread of the virus.

Conflicts of Interest

20%

Examples:

  • Iwasaki is frequently quoted by newspapers and reporters, and has amassed a huge Twitter following of people seeking out her research updates. (Iwasaki believes that public education is a key ingredient for slowing the spread of the virus.)

Contradictions

30%

Examples:

  • Breast cancer, tracheal, bronchus and lung cancers are the deadliest cancers in younger people.
  • The SELECT trial only included participants with established cardiovascular disease and no history of diabetes.

Deceptions

50%

Examples:

  • The deception score is high due to contradictions and potential conflicts of interest.
  • The good news is that in the early spring of 2024, COVID-19 cases were down.

Recent Articles

New Covid FLiRT Variants: Dominant Strains in US and Europe, Potential Impact on Vaccine Effectiveness

New Covid FLiRT Variants: Dominant Strains in US and Europe, Potential Impact on Vaccine Effectiveness

Broke On: Wednesday, 22 May 2024 New Covid FLiRT Variants, KP.2 and KP.1.1, account for over 35% of US Covid-19 cases as of May 2024, surpassing the previously dominant JN.1 strain with similar mutations. These new variants have spread to Europe but currently cause no more severe disease than previous strains, although they may evade immunity from vaccines or past infections. Health officials closely monitor their spread and assess vaccine effectiveness against them.
Early-Onset Cancers: Alarming Increase in Cancer Cases Among Younger Individuals - Prevention and Risk Factors

Early-Onset Cancers: Alarming Increase in Cancer Cases Among Younger Individuals - Prevention and Risk Factors

Broke On: Thursday, 18 April 2024 A rise in early-onset cancers among younger individuals, driven by factors like obesity, sedentary lifestyles, and environmental carcinogens, has shifted cancer demographics. Preventive measures include regular screenings, reducing processed food intake, maintaining a healthy weight, engaging in physical activity, managing stress levels and being aware of family history.
Wegovy Approved to Reduce Heart Complications in Overweight People with Cardiovascular Disease by 20%

Wegovy Approved to Reduce Heart Complications in Overweight People with Cardiovascular Disease by 20%

Broke On: Monday, 18 March 2024 Wegovy, a weight loss drug approved by the FDA for reducing cardiovascular risks in overweight people with heart disease, is now being used to reduce the risk of major heart complications including heart attack, stroke or cardiovascular-related deaths. The new label expansion for Wegovy indicates that it can be used to reduce these risks by 20% in this population. This approval opens up a new market for weight loss drugs and could greatly expand older adults' access to treatments that so far have been limited.